Source-linked dosage record
OZEMPIC dose chart
The Novo Nordisk prescribing record for OZEMPIC (semaglutide), organized into a scan-friendly schedule without detaching it from the source document.
- Ingredient
- semaglutide
- Schedule format
- Label prose rendered as a table
- Label published
- Jun 10, 2026
- Mirrored
- 2026-08-29
Answer first
Dose schedule
The source publishes the sequence in prose. CareCanon displays that rule as 4 inspectable rows.
| Weeks | Dosage | Phase |
|---|---|---|
| 1 through 4 | 0.25 mg | Starting dosage |
| 5 through 8 | 0.5 mg | Dose escalation · label-named maintenance option |
| 9 through 12 | 1 mg | Dose escalation · label-named maintenance option |
| 13 and onward | 2 mg | Maintenance dosage |
The manufacturer does not publish a titration table for OZEMPIC. The label states the escalation as a rule, quoted below, and the schedule above is that rule set out as a table. No dose has been added, and every dose shown appears in the label’s own “Dosage Forms and Strengths” section.
“Initiate OZEMPIC with a dosage of 0.25 mg injected subcutaneously once weekly for 4 weeks. The 0.25 mg dosage is intended for treatment initiation and is not effective for glycemic control. After 4 weeks, increase the dosage to 0.5 mg once weekly.”
Section 3 inventory
Strengths and presentations
This inventory is kept separate from the schedule: a marketed strength is not automatically a starting dose, maintenance dose or recommendation.
Marketed strengths in this brand record
- 0.25 mg
- 0.5 mg
- 1 mg
- 2 mg
Dosage forms
Injection
Named packages
- Single-dose prefilled syringe
Source excerpt · 3 DOSAGE FORMS AND STRENGTHS
Injection: clear, colorless solution available as follows: Single-Patient-Use Pens (with multiple weekly doses) Dose per Injection Total Strength per Total Volume Strength per mL 0.25 mg 0.5 mg 2 mg / 3 mL 0.68 mg/mL 1 mg 4 mg / 3 mL 1.34 mg/mL 2 mg 8 mg / 3 mL 2.68 mg/mL Single-Dose Prefilled Syringes Dose per Injection Total Strength per Total Volume 0.25 mg 0.25 mg / 0.5 mL 0.5 mg 0.5 mg / 0.5 mL 1 mg 1 mg / 0.5 mL • Injection: 2 mg/3 mL (0.68 mg/mL) for 4 doses of 0.25 mg and 2 doses of 0.5 mg or 4 doses of 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 4 doses of 1 mg, and 8 mg/3 mL (2.68 mg/mL) for 4 doses of 2 mg in single-patient-use pens ( 3 ) • Injection: 0.25 mg, 0.5 mg or 1 mg per 0.5 mL in a single-dose prefilled syringe ( 3 )
Inspect the complete section on DailyMed ↗Source excerpts
What the label says
These excerpts preserve the section names used by the source. Open DailyMed for the complete prescribing information.
2 DOSAGE AND ADMINISTRATION
• Administer once weekly at any time of day, with or without meals. ( 2.1 ) • Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly. ( 2.2 ) • If additional glycemic control is needed, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. ( 2.2 ) • If additional glycemic control is needed, increase the dosage to 2 mg once weekly after at least 4 weeks on the 1 mg dosage. ( 2.2 ) • To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 …
2.1 Important Administration Instructions
• Inspect OZEMPIC visually before use. It should appear clear and colorless. Do not use OZEMPIC if particulate matter and coloration is seen. • Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals. • Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm. Instruct patients to use a different injection site each week when injecting in the same body region. • When using OZEMPIC with insulin, instruct patients to administer as separate injections and to never mix the products. It is acceptable to inject OZEMPIC and insulin in the same…
2.2 Recommended Dosage
Recommended Initiation Dosage Initiate OZEMPIC with a dosage of 0.25 mg injected subcutaneously once weekly for 4 weeks. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.7 ), Adverse Reactions ( 6.1 )]. After 4 weeks on the 0.25 mg dosage, increase the dosage to 0.5 mg once weekly. Recommended Maintenance and Maximum Dosages for Glycemic Control The recommended maintenance dosage is 0.5 mg, 1 mg, or 2 mg, injected subcutaneously once weekly, based on glycemic control. If additional glycemic control is needed after at …
Document history
Recent label changes
Only changes named in the label’s own recent-major-changes block appear here.
| Section | Change | Revised |
|---|---|---|
| 5.7 | Warnings and Precautions, Severe Gastrointestinal Adverse Reactions | 10/2025 |
Before using this record
Three useful distinctions
Is this a personal dosing recommendation?
No. It is a reference rendering of prescribing information. A licensed prescriber and pharmacist determine what applies to an individual.
Did the manufacturer publish this exact table?
No. The label states the schedule in prose; CareCanon keeps the source sentence beside the table it renders.
How can I tell whether the source changed?
Use the publication and mirror dates above, inspect the recent-change rows, and open the linked DailyMed record for the current complete document.